Author

G. C. Randall

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. D. Hoffmann· 2 shared D. Fang· 2 shared H. Liu· 2 shared L. El-Shennawy· 2 shared M. G. Ison· 2 shared N. K. Dashzeveg· 2 shared S. Swaminathan· 2 shared V. Nicolaescu· 2 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. D. Hoffmann

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Novel antibody language model accelerates IgG screening and design for broad-spectrum antiviral therapy

H. F. Mubarak, W. Tan, A. D. Hoffmann, Y. Sun, J. Wei, L. El-Shennawy, J. R. Squires, N. K. Dashzeveg, B. Simonton, Y. Jia, R. Iyer, Y. Xu, V. Nicolaescu, D. Elli, G. C. Randall, , Y. Shen

This paper introduces an antibody language model (AbLM) to accelerate IgG screening and design for broad-spectrum antiviral therapy, achieving higher precision in predicting variant-resistant antibodies.

bioRxiv · Mar 1, 2024 · PreprintImmunology

Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Virus Infection as an Innate Antiviral Mechanism

L. El-Shennawy, A. D. Hoffmann, N. K. Dashzeveg, P. J. Mehl, Z. Yu, V. L. Tokars, V. Nicolaescu, C. Ostiguin, Y. Jia, L. Li, K. Furlong, C. Mao, J. Wysocki, D. Batlle, T. J. Hope, , H. Liu

The paper shows that ACE2-expressing exosomes in plasma block SARS-CoV-2 infection by competing with cellular ACE2, offering a new innate antiviral mechanism.

bioRxiv · Dec 3, 2020Immunology